Abstract: An intravenous catheter securement device includes a holder for placement on a bodily appendage near an intravenous insertion site on the bodily appendage, a strap for securing the holder to the bodily appendage, and at least one securement feature formed on the holder and configured to secure at least a portion of an intravenous catheter. The holder is shaped to surround at least a portion of the bodily appendage. The at least one securement feature is a slot formed on the holder. The holder includes a tray having an interior cavity and a tearable lid covering the interior cavity.

Abstract: An intravenous catheter securement sleeve includes a protective cover for placement over a bodily appendage, the protective cover having an opening configured to permit visual of the insertion site of an intravenous catheter on the bodily appendage. A flap is connected to the protective cover and is movable between an open position in which the opening is visually exposed and a closed position in which the opening is concealed. The intravenous catheter securement sleeve further includes at least one monitoring device connected to protective cover and configured to detect at least one functional parameter, and at least one remedy device connected to the protective cover and configured to administer a remedy.

Abstract: A patient monitoring system includes a first imager configured to capture first image data of a target area within a first field of view. A second imager is configured to capture second image data of the target area within a second field of view. An emitter is configured to emit light within a predetermined wavelength range. A controller is configured to determine a facial region of a person in the first image data, determine a region of interest in the second image data that coincides with the facial region in the first image data, calculate a pixel value within the region of interest, adjust at least one of the emitter and the second imager is the pixel value is outside a predetermined pixel value range, and determine vital signs information from at least one of the first image data and the second image data.

Abstract: A method of preventing infections in vascular access devices in which an acoustic wave generator is attached to the vascular access catheter, and the acoustic wave generator is activated to produce acoustic waves, which are transmitted to the vascular access catheter to create mechanical vibrations in the vascular access catheter. The acoustic waves may be ultrasound waves. The acoustic wave generator may be attached to a catheter tube of the vascular access catheter or attached to a hub of the vascular access catheter. The acoustic wave generator a separate device that is removably clipped to the vascular access catheter, may be provided in a vascular access catheter stabilization device or may be integral with the vascular access catheter.

Abstract: A contactless patient monitoring system includes a first imager configured to capture first image data of a target area within a first field of view. A second imager is operably coupled to the first imager. The second imager is configured to capture second image data of the target area within a second field of view. An emitter is operably coupled to at least one of the first imager and the second imager. The emitter is configured to emit light within a predetermined wavelength range. A controller is communicatively coupled to the first imager, the second imager, and the emitter. The controller is configured to determine a facial region of a person in the first image data, determine a region of interest in the second image data that coincides with the facial region in the first image data, and determine a coordinate of a head position within the facial region.

Abstract: Monitoring patient vital signs is performed by analyzing videos recorded of a patient. An algorithm is used to compute the real-time patient vital signs based on video images of the patient. These images can be captured by a video monitoring device positioned over a patient's bed. The video monitoring device can include a thermal camera and a near infrared camera that continuously send video images to a processing unit. The thermal image is used to locate the patient's face and chest. The images are analyzed with an algorithm employed to determine a patient's heart rate, respiration rate, temperature, and body position.

Abstract: A patient monitoring system includes a first imager configured to capture first image data of a target area within a first field of view. A second imager is configured to capture second image data of the target area within a second field of view. An emitter is configured to emit light within a predetermined wavelength range. A controller is configured to determine a facial region of a person in the first image data, determine a region of interest in the second image data that coincides with the facial region in the first image data, calculate a pixel value within the region of interest, adjust at least one of the emitter and the second imager is the pixel value is outside a predetermined pixel value range, and determine vital signs information from at least one of the first image data and the second image data.

Abstract: Provided herein are methods for imaging an optically labeled target cell implanted in vivo using a reporter construct that encodes an enzyme that is not endogenous to the target cell. The disclosed methods include the steps of: (a) introducing target cell transformed with non-endogenous enzyme into a mammalian subject; (b) contacting the transformed target cell with a cell-permeable soluble fluorescent dye; and (c) observing a fluorescent signal generated by the target cell present in the mammalian subject. In some embodiments, the non-endogenous enzyme comprises a nitroreductase. In some embodiments, the methods may also include the step of tracking the fluorescent target cells in the mammalian subject over time.

Abstract: Provided herein are methods of monitoring inflammatory cell migration in a mammal. The methods include the steps of: providing a donor mammalian subject; introducing an inflammatory agent into the donor mammal to create a granuloma; isolating granuloma-derived nucleated cells from the granuloma of the donor mammalian subject; labeling the granuloma-derived nucleated cells with an optical agent; providing a recipient mammalian subject with inflamed tissue; introducing the granuloma-derived nucleated cells into a recipient mammalian subject at a site remote from site where the inflammatory agent was introduced; and imaging the recipient mammalian subject using an optical system. The methods may also include analysing the distribution of the labeled granuloma-derived cells in the recipient mammal.

Abstract: Provided herein are agents that bind to soluble beta-amyloid. Also provided are in vivo and in vitro methods for detecting soluble beta-amyloid in a sample that may include brain tissue.

Abstract: Provided herein are amyloid-binding assays that simulate in situ brain conditions by combining binders with various A-beta species on mammalian brain tissue. In general the amyloid-binding assays comprise the steps of (a) contacting a mammalian brain tissue sample with at least one A-beta species; (b) applying a putative binder to the brain tissue sample; and (c) determining whether the putative binder binds to the A-beta species.

Abstract: Provided herein are agents that bind to soluble beta-amyloid. Also provided are in vivo and in vitro methods for detecting soluble beta-amyloid in a sample that may include brain tissue.

Abstract: Provided herein are methods of monitoring inflammatory cell migration in a mammal. The methods include the steps of: providing a donor mammalian subject; introducing an inflammatory agent into the donor mammal to create a granuloma; isolating granuloma-derived nucleated cells from the granuloma of the donor mammalian subject; labeling the granuloma-derived nucleated cells with an optical agent; providing a recipient mammalian subject with inflamed tissue; introducing the granuloma-derived nucleated cells into a recipient mammalian subject at a site remote from site where the inflammatory agent was introduced; and imaging the recipient mammalian subject using an optical system. The methods may also include analysing the distribution of the labeled granuloma-derived cells in the recipient mammal.

Abstract: Provided herein are methods for imaging an optically labeled target cell implanted in vivo using a reporter construct that encodes an enzyme that is not endogenous to the target cell. The disclosed methods include the steps of: (a) introducing target cell transformed with non-endogenous enzyme into a mammalian subject; (b) contacting the transformed target cell with a cell-permeable soluble fluorescent dye; and (c) observing a fluorescent signal generated by the target cell present in the mammalian subject. In some embodiments, the non-endogenous enzyme comprises a nitroreductase. In some embodiments, the methods may also include the step of tracking the fluorescent target cells in the mammalian subject over time.

Abstract: Provided herein are amyloid-binding assays that simulate in situ brain conditions by combining binders with various A-beta species on mammalian brain tissue. In general the amyloid-binding assays comprise the steps of (a) contacting a mammalian brain tissue sample with at least one A-beta species; (b) applying a putative binder to the brain tissue sample; and (c) determining whether the putative binder binds to the A-beta species.

Abstract: In accordance with one aspect of the present technique, an imaging simulator system comprises a processor assembly that includes a time activity module configured to generate a time activity data, an imager module adapted to receive at least one imager parameter and configured to model the acquisition of an imaging system, and a simulator module adapted to receive at least the time activity data, and the imager model and configured to generate simulated sensed data based on the time activity data, and the imager model.

Abstract: A method for assessing levels of soluble A-beta as an indicator of Alzheimer's disease, and other amyloid-related diseases, in vitro, ex vivo, in vivo, and in situ which employs an imaging agent binds specifically to soluble A-beta and is labeled for detection.

Abstract: A method for assessing levels of soluble A-beta as an indicator of Alzheimer's disease, and other amyloid-related diseases, in vivo which employs an imaging agent binds specifically to soluble A-beta and is labeled for detection.